Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know

Viking Therapeutics (VKTX) gained 1.43% in the latest session, outperforming the S&P 500's 1.06% gain. However, the stock has depreciated 0.03% over the past month, underperforming the Medical sector's 5.75% gain. The company is expected to report an EPS of -$1 (down 23.46% YoY) with full-year consensus estimates of -$4.47 EPS and $0 million revenue. VKTX holds a Zacks Rank #3 (Hold) rating, while its industry (Medical - Biomedical and Genetics) ranks in the bottom 34% of all industries.